proteins news from FierceBiotech

A joint venture between Crucell and DSM Biologics - Percivia -- has produced a new, more efficient approach to manufacturing monoclonal antibodies and proteins. By relying on human cell lines rather Read more...

Targeted Genetics is reporting results from an early-stage study of tgAAC94 for inflammatory arthritis. The drug uses a specially engineered virus to transport a gene. When working properly, the Read more...

Follow-on biologics are often cited as major long-term threat to the biotech industry, which so far has not had to face a future where generic therapies are allowed to slice and dice the market for Read more...

The venture capital arm of GlaxoSmithKline, SR One, has co-led a $33 million venture round for the UK's Syntaxin--a developer focused on cell secretion. The Series B was also co-led by Life Science Read more...

Genetically engineered animals are producing a range of therapies for human use, and The New York Times catches up on the action at companies like Read more...

Analysts were left scratching their heads trying to determine if the FDA's second approvable letter for Neurochem's amyloidosis therapy Kiacta helped or hurt the company. The agency said that there Read more...

Press Release: Crucell N.V. Announces STAR(TM) Research License Agreement With Novo Nordisk

Read more...

Press Release: FivePrime Enters Osteoarthritis and Pulmonary Fibrosis Collaboration With Centocor

Read more...

FivePrime Therapeutics has struck a deal to collaborate with Centocor Research and Development (a Johnson & Johnson company) on the development of new therapies for osteoarthritis and pulmonary fibrosis. Under the collaboration, FivePrime will screen its protein library against cell-based assays directed to osteoarthritis and fibrosis and Centocor will have exclusive rights to the proteins and targets identified in these screens. FivePrime will receive an upfront payment of $15 …

Read more...

Canada's OncoGenex Technologies plans to raise up to $48 million in an IPO. The biotech has three products in development to inhibit the production of proteins linked to the resistance of treatments. The drug developer was founded in 2000 and has raised $35 million in venture capital. RBC Capital Markets will be the sole lead manager for the offering, and Needham & Company, Lazard Capital Markets, Canaccord Adams, and Susquehanna Financial Group are the co-managers.

- see this …

Read more...